2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
COVID-19
2
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
313
Cyclophosphamide
286
fludarabine phosphate
213
fludarabine
140
ibrutinib
121
Peripheral Blood Stem Cell Transplantation
116
venetoclax
108
Mycophenolic Acid
102
obinutuzumab
88
Lenalidomide
88
Bendamustine Hydrochloride
87
Whole-Body Irradiation
85
Filgrastim
84
Tacrolimus
78
Cyclosporine
78
Busulfan
70
Melphalan
65
Radiotherapy
63
Antilymphocyte Serum
61
Alemtuzumab
58
Etoposide
56
acalabrutinib
54
Methotrexate
49
ofatumumab
46
idelalisib
38
Cytarabine
33
Chlorambucil
33
zanubrutinib
31
sargramostim
30
Specimen Handling
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
cilgavimab and tixagevimab drug combination
×
Clear all
NCT05465876
2024-04-04
PACE-CLL
Sunnybrook Health Sciences Centre
Phase 2
Withdrawn